PUBLISHER: The Business Research Company | PRODUCT CODE: 1939323
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939323
A balloon valvuloplasty device is a medical instrument used in the treatment of heart valve stenosis. This procedure involves inserting a balloon into the narrowed valve and inflating it to widen the opening, thereby improving blood flow. It is a minimally invasive approach aimed at relieving symptoms such as chest pain and shortness of breath, ultimately enhancing cardiac function and improving patient quality of life.
The primary types of balloon valvuloplasty devices include standard balloons, cutting balloons, scoring balloons, high-pressure balloons, and low-pressure balloons. Standard balloon valvuloplasty devices are specifically designed to treat narrowed heart valves by expanding the valve opening through balloon inflation. This procedure is commonly performed in minimally invasive settings to alleviate symptoms associated with valve narrowing. These devices are used across pediatric and adult populations and are employed in various healthcare settings including hospitals, ambulatory surgical centers, specialty clinics, and others.
Tariffs are impacting the balloon valvuloplasty device market by increasing costs for catheter shafts, polymer balloon materials, guidewire components, and precision inflation systems sourced across international supply chains, resulting in higher manufacturing and import prices. The effect is more significant for high-pressure, scoring, and cutting balloon product categories, particularly in Asia-Pacific and European manufacturing hubs that rely heavily on imported device components. Hospitals, ambulatory surgical centers, and specialty cardiology clinics are experiencing elevated procurement costs and slower capital purchasing cycles due to tariff-related price pressures. However, tariffs are also encouraging localized device assembly, regional supplier development, and domestic production investments that may strengthen long-term supply resilience and manufacturing competitiveness.
The balloon valvuloplasty device market research report is one of a series of new reports from The Business Research Company that provides balloon valvuloplasty device market statistics, including balloon valvuloplasty device industry global market size, regional shares, competitors with a balloon valvuloplasty device market share, detailed balloon valvuloplasty device market segments, market trends and opportunities, and any further data you may need to thrive in the balloon valvuloplasty device industry. This balloon valvuloplasty device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The balloon valvuloplasty device market size has grown strongly in recent years. It will grow from $2.57 billion in 2025 to $2.73 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rise in prevalence of cardiac valve stenosis, early adoption of minimally invasive interventional cardiology procedures, development of standard and compliant balloon technologies, expansion of hospital-based cardiac catheterization labs, increasing treatment volumes in pediatric congenital heart cases.
The balloon valvuloplasty device market size is expected to see strong growth in the next few years. It will grow to $3.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growing aging population with aortic and mitral valve stenosis, rising demand for high-pressure and scoring balloon devices, wider use of balloon valvuloplasty in ambulatory and specialty clinics, increasing shift toward non-surgical cardiac treatment pathways, ongoing innovation in balloon materials and device design. Major trends in the forecast period include increasing preference for minimally invasive valve repair procedures, rising adoption of balloon valvuloplasty as an alternative to open-heart surgery, growing utilization in pediatric and adult congenital heart valve disorders, expansion of valve dilation procedures in specialty cardiology centers, focus on improving patient outcomes and shorter recovery times.
The growing preference for minimally invasive procedures is anticipated to drive the expansion of the balloon valvuloplasty device market in the coming years. Minimally invasive procedures are medical techniques carried out through small incisions or natural body openings, which reduce tissue damage and support quicker recovery compared to conventional surgeries. The increasing demand for minimally invasive procedures is attributed to shorter recovery periods, a lower risk of complications, and reduced post-operative pain relative to traditional surgical approaches. Balloon valvuloplasty devices are utilized in minimally invasive procedures to dilate narrowed heart valves, enhance blood flow, and alleviate symptoms. For instance, in January 2024, Intuitive Surgical Inc., a US-based manufacturer of robotic surgical products, reported the placement of 415 da Vinci surgical systems in the fourth quarter of 2023, reflecting a 12% increase compared to 2022. Therefore, the rising preference for minimally invasive procedures is fueling the growth of the balloon valvuloplasty device market.
Key players in the balloon valvuloplasty device market are innovating with advanced products such as Pacing Guidewires to maintain competitiveness. Pacing guidewires are specialized tools used during procedures to provide temporary cardiac pacing, ensuring heart stability while balloon catheters dilate narrowed valves. For instance, Teleflex Incorporated, a US-based medical device company, recently received FDA clearance for the Wattson Temporary Pacing Guidewire in June 2023. This device is tailored for use in transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV) procedures, featuring a flexible distal pigtail shape, multiple electrodes, and bipolar design to enhance safety and efficacy. It supports valve delivery and ventricular pacing, reducing the risk of complications such as ventricular perforation and ensuring reliable electrical capture during rapid pacing.
In November 2023, OrbusNeich Medical Group Holdings Limited, headquartered in Hong Kong, acquired Eucatech AG for $2.3 million. This strategic acquisition enhances OrbusNeich's capabilities in providing comprehensive treatment solutions for cardiovascular diseases, bolstering its balloon valvuloplasty device offerings. Eucatech AG, based in Germany, is renowned for its innovative medical technology solutions including balloon valvuloplasty devices.
Major companies operating in the balloon valvuloplasty device market are Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Edwards Lifesciences Corporation, Terumo Corporation, B Braun Melsungen AG, Cook Medical Incorporated, Balton Sp z o o, Meril Life Sciences Pvt Ltd, JenaValve Technology Inc, Osypka Medical GmbH, Scitech Medical, Translumina GmbH, AndraTec GmbH, Palex Medical SA, Biosensors International Group Ltd, Hexacath, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, QT Vascular Ltd
North America was the largest region in the balloon valvuloplasty device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the balloon valvuloplasty device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the balloon valvuloplasty device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The balloon valvuloplasty device market consists of sales of scoring balloons, high-pressure balloons, and standard balloons. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Balloon Valvuloplasty Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses balloon valvuloplasty device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for balloon valvuloplasty device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The balloon valvuloplasty device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.